US-based biotechnology startup Verve has said that its gene-editing drug VERVE-101 can prevent liver cells from producing PCSK9 protein. The drug is designed to change adenine bases in DNA to block PCSK9 gene transcription, which the company said can lead to heart disease. Verve said that initial results from a trial in the UK and…